Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Debt to Equity (2018 - 2022)

Lipocine's Debt to Equity history spans 5 years, with the latest figure at $0.03 for Q1 2022.

  • For Q1 2022, Debt to Equity fell 68.98% year-over-year to $0.03; the TTM value through Mar 2022 reached $0.03, down 68.98%, while the annual FY2021 figure was $0.05, 86.08% down from the prior year.
  • Debt to Equity reached $0.03 in Q1 2022 per LPCN's latest filing, down from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.14 in Q4 2019 to a low of $0.03 in Q1 2022.
  • Average Debt to Equity over 5 years is $0.58, with a median of $0.6 recorded in 2018.
  • Peak YoY movement for Debt to Equity: increased 28.22% in 2020, then crashed 88.38% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $1.09 in 2018, then rose by 4.52% to $1.14 in 2019, then plummeted by 67.95% to $0.36 in 2020, then plummeted by 86.08% to $0.05 in 2021, then tumbled by 31.08% to $0.03 in 2022.
  • Per Business Quant, the three most recent readings for LPCN's Debt to Equity are $0.03 (Q1 2022), $0.05 (Q4 2021), and $0.1 (Q3 2021).